Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin
- 10 November 2018
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 93 (4) , 372-375
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing Enterobacter cloacaeDiagnostic Microbiology and Infectious Disease, 2018
- In Vitro Antibacterial Interaction of Doripenem and Amikacin against Multidrug-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae IsolatesCanadian Journal of Infectious Diseases and Medical Microbiology, 2018
- Effect of the meropenem MIC on the killing activity of meropenem and polymyxin B in combination against KPC-producing Klebsiella pneumoniaeThe Journal of Antibiotics, 2017
- Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal functionEuropean Journal of Clinical Pharmacology, 2016
- Treatment options for infections caused by carbapenem-resistantEnterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy?Expert Opinion on Pharmacotherapy, 2016
- Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patientsJournal of Basic and Clinical Pharmacy, 2016
- In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniaeDiagnostic Microbiology and Infectious Disease, 2013